IVEVF — Inventiva S.A.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1756594 ·
Last close
$5.33
Market Cap
$1.26B
52W High
$5.75
52W Low
$4.44
ADV30
0
Next earnings
2026-03-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 249,511,000 | 99,312,000 | 278,033,000 |
| Jun 2025 | — | — | — | — | 178,955,000 | 122,076,000 | 187,863,000 |
| Dec 2024 | — | — | — | — | 118,967,000 | 96,563,000 | 225,613,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-354,138,000
Inventory
$0
Receivables
$9,121,000
ST Investments
$131,558,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$6,761,000
EBITDA
$-132,497,000
Free Cash Flow
$-200,711,632
Enterprise Value
$961,880,896
Total Cash
$99,839,000
Total Debt
$230,890,000
Shares Out
236,220,651
Trailing EPS
$-2.20
Book Value
$-0.17
ROE
—
ROA
-45.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,483,000 | -132,883,000 | -354,138,000 | 249,511,000 | 278,033,000 | — | -104,884,000 |
| Dec 2024 | 9,198,000 | -93,989,000 | -184,212,000 | 118,967,000 | 225,613,000 | — | -85,928,000 |
| Dec 2023 | 17,477,000 | -102,665,000 | -110,426,000 | 69,561,000 | 101,592,000 | — | -81,614,000 |
| Dec 2022 | 12,179,000 | -56,857,000 | -54,274,000 | 116,004,000 | 70,528,000 | — | -44,928,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.06
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AVLN | Avalyn Pharma Inc. | $1.27B | $28.75 | — |
| MNKD | MANNKIND CORP | $1.24B | $4.00 | — |
| DMRA | Damora Therapeutics, Inc. | $1.24B | $20.07 | — |
| MPLT | MapLight Therapeutics, Inc. | $1.19B | $27.96 | — |
| EVOTF | Evotec SE | $1.19B | $6.69 | — |
News headlines (Yahoo Finance, 1h cache)
Claret Capital Partners participates in €130m financing for Inventiva
2026-06-16 09:12 · Yahoo
Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development
2026-06-16 08:52 · Yahoo
Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing
2026-06-12 20:00 · Yahoo
Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround
2026-06-11 13:35 · Yahoo
Statement of Total Voting Rights and Shares Forming The Company’s Share Capital as of May 22, 2026
2026-06-09 20:00 · Yahoo
Combined General Meeting of June 30, 2026 - Availability of the Preparatory Documents
2026-06-09 20:00 · Yahoo
Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris
2026-06-02 12:30 · Yahoo
Inventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 Readout
2026-06-02 12:29 · Yahoo
Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris
2026-06-02 05:30 · Yahoo
Inventiva Reports 2026 First Quarter Financial Information¹
2026-05-26 20:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.